October 17, 2013 / 5:23 AM / 4 years ago

Actelion confirms outlook as sales rise

ZURICH, Oct 17 (Reuters) - Actelion, Europe's largest biotech company, confirmed its full-year outlook on Thursday ahead of a widely anticipated approval of its big drug hope Opsumit by U.S. health regulators later this week.

Nine month sales of its main product Tracleer, a treatment for pulmonary arterial hypertension (PAH), rose 3 percent to 1.138 billion Swiss francs, while net profit was 304 million francs.

Actelion confirmed its forecast for core earnings to cross into the double-digit percentage range for 2013. (Reporting by Alice Baghdjian and Caroline Copley)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below